http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
불평형 전원 조건에서 MMC HVDC 시스템 전력제어를 고려한 순환전류 분석 및 제어
도원석(Won-Seok Do),김시환(Si-Hwan Kim),김태진(Tae-Jin Kim),김래영(Rae-Young Kim) 대한전기학회 2014 대한전기학회 학술대회 논문집 Vol.2014 No.4
본 논문은 불평형 계통 전원 조건에서 모듈형 멀티레벨 컨버터를 이용한 HVDC 시스템의 순환전류에 대한 분석을 보여주고 있다. 먼저 모듈형 멀티레벨 HVDC 시스템의 기본 구조 및 시스템 동특성에 대해 해석을 하고, 이러한 해석을 바탕으로 불평형 계통 전원에 사용되는 대표적인 전력 제어기를 대상으로 정상 및 불평형 계통 전원 조건하에서의 순환전류의 모델링과 이에 대한 해석을 제안한다. 이를 통해 전력 제어기의 적용을 위해 실제적으로 고려되어야 할 사항을 시뮬레이션을 통하여 검증한다.
도원석,이종학,김경주,한만훈,정희연,최지영,박선희,김용림,김찬덕,조장희,양영애,김민정,황인량,김규연,임태훈,김용진 대한이식학회 2018 Korean Journal of Transplantation Vol.32 No.3
A 38-year-old man, who underwent a second kidney transplantation (KT), was admitted because of antibody-mediated rejection (AMR) complicated by BK virus-associated nephropathy (BKVAN). He was placed on hemodialysis at the age of 24 years because of membranoproliferative glomerulonephritis. At the age of 28 years, he underwent a living donor KT from his father; however, 1 year after the transplantation, he developed a recurrence of the primary glomerular disease, resulting in graft failure 2 years after the first KT. Ten years later, he received a deceased-donor kidney with a B-cell-positive-cross-match. He received 600 mg of rituximab before the KT with three cycles of plasmapheresis and immunoglobulin (0.5 g/kg) therapy after KT. During the follow-up, the first and second allograft biopsies at 4 and 10 months after KT revealed AMR with a recurrence of primary glomerular disease that was reclassified as C3 glomerulonephritis (C3GN). He received a steroid pulse, rituximab, plasmapheresis, and immunoglobulin therapies. The third allograft biopsy demonstrated that the BKVAN was complicated with AMR and C3GN. As the azotemia did not improve after repeated conventional therapies for AMR, one cycle of bortezomib (1.3 mg/m2×4 doses) was administered. The allograft function stabilized, and BK viremia became undetectable after 6 months. The present case suggests that bortezomib therapy may be applicable to patients with refractory AMR, even in cases complicated with BKVAN.